Imagine your body turning on itself, causing waves of high fever, painful rashes, and debilitating joint pain. That's the reality for people with Adult-Onset Still's Disease (AOSD), a rare inflammatory condition. A recent study looked at whether a monthly injection called canakinumab could help Japanese patients with this disease. The treatment was given just under the skin every four weeks for at least a year. The study was designed to see how well it worked, how safe it was, and how the body processed the drug. The main goal was to see how many people had a meaningful improvement in their symptoms—specifically, at least a 30% reduction in disease activity—by the eighth week of treatment. While the abstract doesn't give the exact percentage of people who improved, it does report that the data collected at 28 weeks and again at 48 weeks were strong enough to support submitting the drug for official approval to treat AOSD in Japan. This is a key step, as it means regulators saw enough evidence that the treatment could be beneficial. The study involved 14 participants and followed them closely during the treatment period.
Could a monthly injection help control the painful flares of Adult-Onset Still's Disease?
Plain Language Summary
What this means for you:
Study data supported the use of a monthly injection for Adult-Onset Still's Disease in Japan. What this means for you:
Study data supported the use of a monthly injection for Adult-Onset Still's Disease in Japan. View Original Abstract ↓
Status: COMPLETED | Phase: PHASE3
Condition(s): Adult Onset Still's Disease
Intervention(s): Canakinumab (BIOLOGICAL)
This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD).
Interim analysis data collected at Weeks 28 and 48 supported the registration submission of canakinumab for the indication of Adult Still's Disease (ASD) in Japan.
Detailed: This was a Phase III, open-label, single-arm active treatment study designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of canakinumab at a dose of 4 mg/kg (up to a maximum of 300 mg) administered subcutaneously every 4 weeks for at least 48 weeks in Japanese participants with ASD.
The study consisted of two epochs:
* Screening epoch: Day -28 to Day -1
* Open-label treatment epoch: Day 1 until either regulatory approval and commercial availability of canakinumab for adult Still's disease (ASD) in Japan, or study termination (whichever occurred first).
Primary Outcome(s): Percentage of Participants Who Achieved Adapted American College of Rheumatology (ACR) 30 Response at Week 8
Enrollment: 14 (ACTUAL)
Lead Sponsor: Novartis Pharmaceuticals
Start: 2021-03-30 | Primary Completion: 2025-04-16
Results posted: 2026-03-23